<DOC>
	<DOCNO>NCT00059865</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy gemcitabine work different way stop tumor cell divide stop grow die . Pemetrexed disodium may stop growth tumor cell block enzymes necessary tumor cell growth . Combining gemcitabine pemetrexed disodium may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose gemcitabine give together pemetrexed disodium see well work treat patient unresectable metastatic biliary tract gallbladder cancer .</brief_summary>
	<brief_title>Gemcitabine Plus Pemetrexed Disodium Treating Patients With Unresectable Metastatic Biliary Tract Gallbladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose gemcitabine administer pemetrexed disodium patient unresectable metastatic biliary tract gallbladder cancer . ( Phase I close accrual Oct . 2005 . ) - Determine 6-month survival rate patient treat regimen . - Determine best objective tumor response rate duration best objective tumor response patient treat regimen . - Determine time progression overall survival patient treat regimen . - Determine toxic effect regimen patient . - Determine individual patient variation toxicity and/or response regimen due genetic difference proteins involved drug response patient . OUTLINE : This multicenter phase I dose-escalation study gemcitabine follow phase II study . - Phase I : Patients receive pemetrexed disodium IV 10 minute gemcitabine IV 30 minute day 1 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity ( phase I close accrual October 2005 ) . Cohorts 3-6 patient receive escalate dos gemcitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive pemetrexed disodium phase I gemcitabine recommended phase II dose . Patients follow every 3 month 1 year every 6 month 4 year . PROJECTED ACCRUAL : A total 85 patient accrue study .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>One follow histologically cytologically confirm cancer amenable treatment combine chemotherapy radiotherapy : Biliary tract ( intrahepatic , extrahepatic , ampulla Vater ) carcinoma Gallbladder carcinoma Unresectable metastatic disease No CNS metastases Prior brain metastasis treat surgery radiosurgery allow provide treatment complete least 4 week ago evidence CNS progression No clinically significant pericardial pleural effusion ascites unless able drain study entry Performance status ECOG 02 At least 3 month Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 3 time upper limit normal ( ULN ) AST great 5 time ULN Creatinine great 1.5 time ULN Creatinine clearance least 45 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer Able tolerate folic acid , corticosteroid , cyanocobalamin supplement More 4 week since prior biologic immunologic therapy No prior biologic immunologic therapy metastatic disease No concurrent immunotherapy No concurrent colonystimulating factor course 1 No prior chemotherapy metastatic disease No prior gemcitabine Prior chemoembolization allow provided follow true : At least 4 week since prior chemoembolization Evidence new tumor growth since therapy At least 6 month since prior chemotherapy use radiosensitizer ( adjuvant set locally advanced disease ) No concurrent chemotherapy Prior radiofrequency ablation allow provide follow true : At least 4 week since prior radiofrequency ablation Evidence new tumor growth since therapy No prior radiotherapy 25 % bone marrow More 4 week since prior radiotherapy No concurrent radiotherapy Prior embolization allow provided follow true : At least 4 week since prior embolization Evidence new tumor growth since therapy No prior pemetrexed disodium No aspirin nonsteroidal antiinflammatory drug least 2 day ( 5 day longacting agent [ e.g. , piroxicam ] ) , , least 2 day administration pemetrexed disodium No concurrent cyclooxygenase2 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>adult primary cholangiocellular carcinoma</keyword>
</DOC>